Links WebJust another WordPress weblog

SCOTTSDALE, Ariz., May 20 /PRNewswire/ — Regenesis Biomedical, Inc., a medical technology company that markets the Provant(R) Wound Therapy System, announced today the formation of a Scientific Advisory Board. The Board’s purpose is to guide advanced scientific investigations into the mechanism of action of Provant, new product development, and further application of Regenesis’ platform technology to clinical and industrial applications.
(Photo: )
“This is another milestone in Regenesis’ strategic plan to advance the science of wound care,” said Virginia Rybski, Acting President of Regenesis. “Our Scientific Advisory Board is composed of academics and thought leaders who are experts in the field of bioelectrochemistry, which is the interaction between energy and living systems. This group will assist in our evidenced- based decision-making as we further expand our platform technology into next generation products.”
The Regenesis Scientific Advisory Board brings together experts recognized in their fields:
* Metin Akay, Ph.D., Professor and Chairman of the Harrington Department
of Bioengineering at Arizona State University, and founding chairman of
the International IEEE Conference on Neural Engineering.
* Hunt Dabney, President, Hunt Dabney & Associates. Leading expert in
precision medical electronics and regulatory compliance mitigation.
Holds 7 US patents with 7 patents pending.
* Colin McCaig, Ph.D., Professor of Physiology and Head of School of
Medical Sciences at the University of Aberdeen, Scotland. Researches
role of endogenous direct current electrical fields in development and
regeneration of tissues in cell culture, excised tissues and whole
animals.
* Dennis Orgill, M.D., Ph.D., Associate Professor at Harvard Medical
School, Associate Chief of Plastic Surgery and Principal Investigator
of the Wound Healing and Tissue Engineering Laboratory at Brigham and
Women’s Hospital.

About the Provant Wound Therapy System

Provant delivers cell proliferation induction(R) (CPI(R)) therapy based on Regenesis’ proprietary pulsed radio frequency energy (PRFE) core technology platform. PRFE uses an optimized radiofrequency signal to stimulate dormant cells, causing them to replicate and to produce natural growth factors and other gene expression products, which facilitate reduction of the pain and edema associated with post-operative wound healing in soft tissues. We believe Provant is effective, economical, and easy-to-use.
About Regenesis Biomedical
Regenesis Biomedical, Inc. is a privately held medical technology company focused on developing and marketing noninvasive regenerative medicine products. Regenesis developed, patented, and now markets the Provant Wound Therapy System. Our customers include health care facilities and providers that serve patients with wounds being treated by acute care hospitals, long- term acute care hospitals, skilled nursing facilities, rehabilitation centers, home health care agencies, and wound care clinics.
Contact:
Regenesis Biomedical, Inc.
Media: Scott Robey, VP Marketing
Clinicians: Rick Isenberg, MD, VP Clinical Affairs

Investors: Virginia Rybski, Acting President

480-970-4970

Regenesis Biomedical, Inc.

MELVILLE, N.Y., April 4, 2008 /PRNewswire-FirstCall/ — Gentiva Health Services, Inc. , the nation’s leading provider of comprehensive home health services, announced today that it is scheduled to present from 8 a.m. to 8:40 a.m. ET, Wednesday, April 16, 2008 at the SunTrust Robinson Humphrey 37th Annual Institutional Unconference in Atlanta.The presentation will be available to the public via a live audio web cast, which may be accessed by visiting to register for the live event or listen to the archived version. Visitors to this site will also be able to request advance notifications of this and other upcoming Gentiva events.Gentiva executives will give attendees an overview of the Company’s operations and strategic priorities, and review opportunities for growth as the U.S. home health industry provides more services to an aging population.About Gentiva Health Services, Inc.Gentiva Health Services, Inc. is the nation’s leading provider of comprehensive home health services. The Company serves patients across the United States, through its direct service delivery units or through CareCentrix(R), which manages home health services for major managed care organizations. Gentiva is a single source for skilled nursing; physical, occupational, speech and neurorehabilitation services; hospice services; social work; nutrition; disease management education; help with daily living activities; respiratory therapy and home medical equipment; infusion therapy services; and other therapies and services. Gentiva’s revenues are generated from federal and state government programs, commercial insurance and individual consumers. For more information, visit Gentiva’s web site, , and its investor relations section at . GTIV-GForward-Looking StatementCertain statements contained in this news release, including, without limitation, statements containing the words “believes,”"anticipates,”"intends,”"expects,”"assumes,”"trends” and similar expressions, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based upon the Company’s current plans, expectations and projections about future events. However, such statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others: the Company’s ability to successfully execute its growth strategy; the impact of significant indebtedness on the Company’s liquidity and its ability to meet the requirements of its creditors; general economic and business conditions; demographic changes; changes in, or failure to comply with, existing governmental regulations; legislative proposals for healthcare reform; changes in Medicare and Medicaid reimbursement levels; effects of competition in the markets in which the Company operates; liability and other claims asserted against the Company; ability to attract and retain qualified personnel; availability and terms of capital; loss of significant contracts or reduction in revenues associated with major payer sources; ability of customers to pay for services; business disruption due to implementation of new business systems, or due to natural disasters or terrorist acts; a material shift in utilization within capitated agreements; and changes in estimates and judgments associated with critical accounting policies and estimates. For a detailed discussion of certain of these and other factors that could cause actual results to differ from those contained in this news release, please refer to the Company’s various filings with the Securities and Exchange Commission (SEC), including the “Risk Factors” section contained in the Company’s annual report on Form 10-K for the year ended December 30, 2007. Financial and Investor Contact: John R. Potapchuk 631-501-7035 Media Contact: David Fluhrer 631-501-7102 516-589-0778Gentiva Health Services, Inc.

MUNICH, Germany, March 31 /PRNewswire-FirstCall/ — Thermo Fisher Scientific Inc. , the world leader in serving science, today launched a number of innovative new products at Analytica 2008, the world’s largest laboratory technology tradeshow, taking place in Munich, Germany, from April 1 - 4. The company’s new technologies are focused on enabling customers to take advantage of the most advanced solutions available for their application — from complex research to routine analysis.”Today, we are unveiling in Europe novel tools that are built upon decades of experience in working with our customers to move science forward,” said Marc N. Casper, executive vice president of Thermo Fisher Scientific. “We’re excited to showcase breakthroughs covering a range of technology platforms, from RNA-interference to elemental analysis, molecular spectroscopy and mass spectrometry. You will also see how our technologies fit together to form a complete workflow, with a comprehensive protein research laboratory replicated in our booth.”Furthermore, we continue to make strategic acquisitions that complement our technology breadth and strengthen our geographic market position. For example, our additions of NanoDrop micro UV-Vis systems, as well as Flux and La-Pha-Pack chromatography products and consumables, will allow us to more effectively deliver our unmatched offerings to customers in Europe and around the world.”The industry-leading portfolio of laboratory offerings from the company’s premier brands, Thermo Scientific and Fisher Scientific, is on display in booths 105/204 and 121/220 in Hall B1. Among the new technologies, products and capabilities introduced this year are: Elemental Analysis Thermo Scientific iCE 3000 Series of Atomic Absorption (AA) spectrometers — comprising the new iCE 3300, iCE 3400 and iCE 3500, the innovative iCE 3000 Series has been designed to facilitate prolonged and simplified operation — even using the most difficult samples — with superior functionality. These new AA spectrometers are the most compact available and have been developed to accommodate both flame and furnace analyses. The new Thermo Scientific AA instruments primarily address the analytical needs of users working in the food safety industry, as well as the environmental, clinical, pharmaceutical, metals and materials industries. Molecular Spectroscopy Thermo Scientific Nicolet(TM) iS(TM)10 FT-IR spectrometer — powered by new OMNIC(TM) Specta(TM) software, this easy-to-use system simplifies advanced spectroscopy, enabling chemists in analytical and investigative chemistry laboratories to take advantage of the power of FT-IR. Thermo Scientific Nicolet(TM) iN(TM)10 FT-IR microscope — powered by new OMNIC(TM) Picta(TM) software, this FT-IR microscope is a significant development that simplifies infrared microscopy for chemists in analytical and investigative chemistry laboratories. The enhanced iN10 MX version provides new levels of imaging performance to microscopy and chemical imaging, without the need for an external FT-IR spectrometer. Thermo Scientific DXR SmartRaman spectrometer — a new Raman platform designed specifically for the needs and environment of the quality control (QC) laboratory, it will enable many QC labs to harness the power of the Raman technique for the first time. Thermo Scientific DXR Raman microscope — designed to help non- specialist users perform rapid sampling and analysis of small features, down to one-micron spatial resolution, this novel microscope also offers superior overall performance and outstanding reproducibility in a package that anyone can use. UV-Vis Spectroscopy Thermo Scientific NanoDrop line of micro-volume spectroscopy systems — these unique instruments use a patented technology that enables easy measurement of UV-Vis and fluorescence by eliminating the use of cuvettes and associated dilutions. The systems are designed for applications involving small sample volumes, increasingly required in emerging life sciences research that involves measurement of DNA and proteins. Mass Spectrometry Thermo Scientific LTQ Orbitrap(R) XL(TM) ETD and Thermo Scientific MALDI LTQ Orbitrap — these advancements bring electron transfer dissociation (ETD) and matrix-assisted laser desorption/ionization (MALDI) capabilities to the award-winning LTQ Orbitrap hybrid series of mass spectrometers. The LTQ Orbitrap XL ETD is the only ETD instrument with both high resolution and accurate mass, enabling the ultimate in definitive protein characterization. The new MALDI LTQ Orbitrap series accelerates the analysis of whole tissue, biological and polymer samples by leveraging the ultrahigh resolution and accurate mass Orbitrap capabilities. RNAi Technology Thermo Scientific Dharmacon Accell(TM) siRNA — RNA-interference (RNAi) is a powerful technology used to silence, or knock down, target genes and the proteins they produce, revealing their role in biological pathways and disease processes. Accell is a breakthrough gene-silencing tool that greatly simplifies RNAi technology and eliminates barriers associated with previous cellular delivery methods. The technology is expected to accelerate research and drug discovery in many important life sciences fields, including neuroscience, immunology, stem-cell science and oncology. Liquid Handling and Consumables Thermo Scientific Finnpipette F1 and F2 Series — the result of more than 40 years of pipetting expertise, the new Finnpipette F-Series includes variable and fixed volume single-channel models covering 0.2 microliters to 10 ml for assured versatility. Furthermore, multi-channel models are available and include 8-, 12- and 16-channel pipettes covering 1-300 microliters for even greater flexibility. The new F- Series offers superior accuracy and the highest levels of pipetting precision for both routine use and for quality-conscious research and pharma-biotechnology laboratories. Informatics Darwin LIMS(TM) 3.0 laboratory information management system — brings significant functionality enhancements to the pharmaceutical industry through a purpose-built LIMS designed specifically for QA/QC, offering environmental monitoring, dissolution, stability management, product and batch management and system interfacing.For full press releases announcing all new products at Analytica 2008, please visit the online media room at .About Thermo Fisher ScientificThermo Fisher Scientific Inc. is the world leader in serving science, enabling our customers to make the world healthier, cleaner and safer. With annual revenues of $10 billion, we have more than 30,000 employees and serve over 350,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental and industrial process control settings. Serving customers through two premier brands, Thermo Scientific and Fisher Scientific, we help solve analytical challenges from routine testing to complex research and discovery. Thermo Scientific offers customers a complete range of high-end analytical instruments as well as laboratory equipment, software, services, consumables and reagents to enable integrated laboratory workflow solutions. Fisher Scientific provides a complete portfolio of laboratory equipment, chemicals, supplies and services used in healthcare, scientific research, safety and education. Together, we offer the most convenient purchasing options to customers and continuously advance our technologies to accelerate the pace of scientific discovery, enhance value for customers and fuel growth for shareholders and employees alike. Visit .The following constitutes a “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward- looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the company’s Annual Report on Form 10-K for the year ended December 31, 2007, under the caption “Risk Factors,” which is on file with the Securities and Exchange Commission (SEC) and available in the “Investors” section of our Website under the heading “SEC Filings.” We also may make forward-looking statements about the benefits of the merger of Thermo Electron and Fisher Scientific, including statements about future financial and operating results, the new company’s plans, objectives, expectations and intentions and other statements that are not historical facts. Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the risk that the businesses will not be integrated successfully; the risk that the cost savings and any other synergies from the transaction may not be fully realized or may take longer to realize than expected; disruption from the transaction making it more difficult to maintain relationships with customers, employees or suppliers; competition and its effect on pricing, spending, third-party relationships and revenues; the need to develop new products and adapt to significant technological change; implementation of strategies for improving internal growth; use and protection of intellectual property; dependence on customers’ capital spending policies and government funding policies; realization of potential future savings from new productivity initiatives; general worldwide economic conditions and related uncertainties; the effect of changes in governmental regulations; the effect of exchange rate fluctuations on international operations; the effect of laws and regulations governing government contracts; the effect of competing with certain of our customers and suppliers; and the effect of rapid changes in the healthcare industry. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change and, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today. Media Contact Information: Lori Gorski Phone: 781-622-1242 E-mail: Website: Investor Contact Information: Ken Apicerno Phone: 781-622-1111 E-mail: Thermo Fisher Scientific Inc.

VIENNA, Va., March 24 /PRNewswire-FirstCall/ — CMPMedica has expanded SearchMedica.com to include a number of additional vertical search applications for specialist medical conditions. SearchMedica.com was co- developed with Convera Corporation , , a leading provider of vertical search services for publishers.(Logo: )SearchMedica.com has been serving primary health care professionals in North America, the UK, France and Spain, and Psychiatry and Oncology specialists in North America. Since its launch in late 2006, the popularity of the service has risen dramatically and today generates millions of queries per month.”We are delighted by the very positive reaction from the medical community as well as from our commercial partners,” said Phil Callow, Managing Director of SearchMedica. “Based on user surveys and feedback, we’ve decided to add further disease-focused custom search functionality so that our full range now includes All of Medicine, Cardiovascular, Diabetes/Endocrine, Infectious, Mental/Nervous System, Musculoskeletal, Cancer/Hemic, Pediatric and Respiratory. This extension is part of CMPMedica’s ongoing strategy to widen the scope of the service to satisfy the information and workflow requirements of every major medical domain.”SearchMedica.com , which was co-developed with Convera, is an advertising supported Web-based service that connects physicians and other medical professionals to credible, trusted and editorially approved medical Web sites, online journals and other clinical resources.About CMPMedicaCMPMedica provides information and education to healthcare professionals and patients around the world. It has a unique portfolio of professional media products including newspapers, magazines, drug directories, electronic databases, websites and events.About SearchMedica.comSearchMedica.com indexes only authoritative medical information, approved for inclusion by medical editors and a physician editorial board. Medical professionals receive more relevant, smaller sets of search results from SearchMedica.com than from mainstream engines, which contain consumer- oriented, paid testimonials and other types of unreliable information. Since SearchMedica.com is advertiser supported, medical professionals pay nothing to use the specialty search engine. All SearchMedica search results are independent and unbiased. They contain well-known, credible journals, peer- reviewed research, and evidence-based articles written for practicing healthcare professionals. SearchMedica is currently available at .About Convera(R)Convera is the leading provider of search as a service for trade publishers and is the vertical search provider of choice for a growing number of specialist publishers around the world. Convera enables publishers to generate additional revenue by creating customized search applications for specialist audiences under their own brand and also manages the vertical search sites of a growing number of specialist publishers. Convera site search, vertical search and lead generation applications can combine publisher proprietary content with an editorially vetted best of the Web for specific professional audiences, providing an authoritative and comprehensive search experience. Many of the world’s largest publishers are working with Convera to accelerate their e-publishing strategies, meet growing online revenue goals and build loyal online professional communities.This release, including any statements from Convera personnel, contains statements about Convera’s future expectations, performance, plans, and prospects, as well as assumptions about future events. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including without limitation, business and economic conditions and trends; the ability to continue funding operating losses; fluctuations in operating results including impacts from reduced corporate IT spending and lengthier sales cycles; continued success in technological advances and development; possible disruption in commercial activities caused by terrorist activity and armed conflict, such as changes in logistics and security arrangements; reduced customer demand relative to expectations; competitive factors; and other risk factors listed from time to time in the company’s reports to the Securities and Exchange Commission. Actual results may differ materially from our expectations as the result of these and other important factors relating to Convera’s business and product development efforts, which are further described in Convera’s filings with the SEC. These filings can be obtained from the SEC’s website located at . Any forward-looking statements are based on information available to Convera on the date of this release, and Convera assumes no obligation to update such statements. Convera(R) and the Convera design logo are trademarks of Convera in the United States and other countries. Convera